In a recent case series, researchers described three patients who developed irreversible vision loss after receiving additional doses of intravitreal faricimab following an initial episode of mild intraocular inflammation (IOI). They aimed to assess the clinical course of patients who developed occlusive retinal vasculitis (ORV) after an initial episode of mild IOI, as well as any potential immunologic mechanisms that might contribute to ORV development upon retreatment, and safety considerations regarding rechallenging patients who had prior IOI from antivascular endothelial growth factor (VEGF) agents.

Source: JAMA Ophthalmology